Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.

Researchers studied the relationship between 3 dermatological immune-mediated inflammatory diseases and COVID-19.

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...

Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...

Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low dise ...

Tralokinumab is effective in severe atopic dermatitis for up to 18 months, with patients who are naïve to some medications having faster benefits.

Arcutis shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate ...

Ocular surface disease symptoms in individuals with comorbid atopic dermatitis are more common and severe, and self-rated vision is worse.

The only change she mentioned was, because it was frigid outside, she and her friends were going to the mall a lot where they ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...